New strategies are needed in diffuse malignant mesothelioma

K. S. Sridhar, R. Doria, W. A. Raub, Richard J Thurer, M. Saldana

Research output: Contribution to journalArticle

92 Citations (Scopus)

Abstract

Background. Medical records of 50 patients with malignant mesothelioma were reviewed to determine the clinical features and factors influencing survival. Methods. Charts of all patients whose conditions were diagnosed as malignant mesothelioma were abstracted and analyzed by statistical software. Results. The male-to-female ratio was 4:1. The age distribution was younger than 45 years of age, 10%; 45-54 years of age, 12%; 55-64 years of age, 37%; 65-74 years of age, 33%; and 75 years of age or older, 8%. Both mean and median ages were 58 years. Among the 32 patients in whom asbestos exposure was recorded, 24 had documented exposure. The sites were pleura, 73%; peritoneum, 20%; and both, 6%. The histologic types were epithelial, 51%; sarcomatous, 10%; mixed, 15%; and not specified, 24%. The stage at presentation was Stage I, 37%; II, 39%; III, 12%; IV, 6%; and unknown, 6%. The common symptoms in pleural disease were dyspnea and pain; in peritoneal disease, abdominal distension and pain were common. The median time from first symptom to diagnosis was 3 months (range, 0-23 months). The median survival after the appearance of symptoms, the diagnosis, and the treatment were 13, 10, and 8 months, respectively. Conclusions. The survival was independent of age, sex, and smoking behavior. It was longer in patients with earlier-stage disease, a good performance status, a longer duration of symptoms, an absence of pain, and who were treated with combined surgery and chemotherapy. Chemotherapy using anthracyclines yielded more remissions (9 of 21) than that using nonanthracyclines (0 of 13). The remission rate after primary chemotherapy with anthracyclines (7 of 16) may be higher than in recurrent tumor (2 of 14). In future trials, stratification into primary chemotherapy and chemotherapy of recurrent cancer is suggested. There is a need for multitechnique trials incorporating primary chemotherapy.

Original languageEnglish
Pages (from-to)2969-2979
Number of pages11
JournalCancer
Volume70
Issue number12
DOIs
StatePublished - Dec 22 1992

Fingerprint

Drug Therapy
Anthracyclines
Survival
Peritoneal Diseases
Pleural Diseases
Pain
Pleura
Peritoneum
Asbestos
Age Distribution
Sexual Behavior
Dyspnea
Abdominal Pain
Medical Records
Malignant Mesothelioma
Neoplasms
Software
Smoking
Therapeutics

Keywords

  • doxorubicin
  • mesothelioma
  • metachronous cancers
  • multitechnique therapy
  • pirarubicin
  • primary chemotherapy
  • prochlorperazine

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Sridhar, K. S., Doria, R., Raub, W. A., Thurer, R. J., & Saldana, M. (1992). New strategies are needed in diffuse malignant mesothelioma. Cancer, 70(12), 2969-2979. https://doi.org/10.1002/1097-0142(19921215)70:12<2969::AID-CNCR2820701239>3.0.CO;2-A

New strategies are needed in diffuse malignant mesothelioma. / Sridhar, K. S.; Doria, R.; Raub, W. A.; Thurer, Richard J; Saldana, M.

In: Cancer, Vol. 70, No. 12, 22.12.1992, p. 2969-2979.

Research output: Contribution to journalArticle

Sridhar, KS, Doria, R, Raub, WA, Thurer, RJ & Saldana, M 1992, 'New strategies are needed in diffuse malignant mesothelioma', Cancer, vol. 70, no. 12, pp. 2969-2979. https://doi.org/10.1002/1097-0142(19921215)70:12<2969::AID-CNCR2820701239>3.0.CO;2-A
Sridhar, K. S. ; Doria, R. ; Raub, W. A. ; Thurer, Richard J ; Saldana, M. / New strategies are needed in diffuse malignant mesothelioma. In: Cancer. 1992 ; Vol. 70, No. 12. pp. 2969-2979.
@article{814eb4691ace449989a92eaedd8b9e8e,
title = "New strategies are needed in diffuse malignant mesothelioma",
abstract = "Background. Medical records of 50 patients with malignant mesothelioma were reviewed to determine the clinical features and factors influencing survival. Methods. Charts of all patients whose conditions were diagnosed as malignant mesothelioma were abstracted and analyzed by statistical software. Results. The male-to-female ratio was 4:1. The age distribution was younger than 45 years of age, 10{\%}; 45-54 years of age, 12{\%}; 55-64 years of age, 37{\%}; 65-74 years of age, 33{\%}; and 75 years of age or older, 8{\%}. Both mean and median ages were 58 years. Among the 32 patients in whom asbestos exposure was recorded, 24 had documented exposure. The sites were pleura, 73{\%}; peritoneum, 20{\%}; and both, 6{\%}. The histologic types were epithelial, 51{\%}; sarcomatous, 10{\%}; mixed, 15{\%}; and not specified, 24{\%}. The stage at presentation was Stage I, 37{\%}; II, 39{\%}; III, 12{\%}; IV, 6{\%}; and unknown, 6{\%}. The common symptoms in pleural disease were dyspnea and pain; in peritoneal disease, abdominal distension and pain were common. The median time from first symptom to diagnosis was 3 months (range, 0-23 months). The median survival after the appearance of symptoms, the diagnosis, and the treatment were 13, 10, and 8 months, respectively. Conclusions. The survival was independent of age, sex, and smoking behavior. It was longer in patients with earlier-stage disease, a good performance status, a longer duration of symptoms, an absence of pain, and who were treated with combined surgery and chemotherapy. Chemotherapy using anthracyclines yielded more remissions (9 of 21) than that using nonanthracyclines (0 of 13). The remission rate after primary chemotherapy with anthracyclines (7 of 16) may be higher than in recurrent tumor (2 of 14). In future trials, stratification into primary chemotherapy and chemotherapy of recurrent cancer is suggested. There is a need for multitechnique trials incorporating primary chemotherapy.",
keywords = "doxorubicin, mesothelioma, metachronous cancers, multitechnique therapy, pirarubicin, primary chemotherapy, prochlorperazine",
author = "Sridhar, {K. S.} and R. Doria and Raub, {W. A.} and Thurer, {Richard J} and M. Saldana",
year = "1992",
month = "12",
day = "22",
doi = "10.1002/1097-0142(19921215)70:12<2969::AID-CNCR2820701239>3.0.CO;2-A",
language = "English",
volume = "70",
pages = "2969--2979",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "12",

}

TY - JOUR

T1 - New strategies are needed in diffuse malignant mesothelioma

AU - Sridhar, K. S.

AU - Doria, R.

AU - Raub, W. A.

AU - Thurer, Richard J

AU - Saldana, M.

PY - 1992/12/22

Y1 - 1992/12/22

N2 - Background. Medical records of 50 patients with malignant mesothelioma were reviewed to determine the clinical features and factors influencing survival. Methods. Charts of all patients whose conditions were diagnosed as malignant mesothelioma were abstracted and analyzed by statistical software. Results. The male-to-female ratio was 4:1. The age distribution was younger than 45 years of age, 10%; 45-54 years of age, 12%; 55-64 years of age, 37%; 65-74 years of age, 33%; and 75 years of age or older, 8%. Both mean and median ages were 58 years. Among the 32 patients in whom asbestos exposure was recorded, 24 had documented exposure. The sites were pleura, 73%; peritoneum, 20%; and both, 6%. The histologic types were epithelial, 51%; sarcomatous, 10%; mixed, 15%; and not specified, 24%. The stage at presentation was Stage I, 37%; II, 39%; III, 12%; IV, 6%; and unknown, 6%. The common symptoms in pleural disease were dyspnea and pain; in peritoneal disease, abdominal distension and pain were common. The median time from first symptom to diagnosis was 3 months (range, 0-23 months). The median survival after the appearance of symptoms, the diagnosis, and the treatment were 13, 10, and 8 months, respectively. Conclusions. The survival was independent of age, sex, and smoking behavior. It was longer in patients with earlier-stage disease, a good performance status, a longer duration of symptoms, an absence of pain, and who were treated with combined surgery and chemotherapy. Chemotherapy using anthracyclines yielded more remissions (9 of 21) than that using nonanthracyclines (0 of 13). The remission rate after primary chemotherapy with anthracyclines (7 of 16) may be higher than in recurrent tumor (2 of 14). In future trials, stratification into primary chemotherapy and chemotherapy of recurrent cancer is suggested. There is a need for multitechnique trials incorporating primary chemotherapy.

AB - Background. Medical records of 50 patients with malignant mesothelioma were reviewed to determine the clinical features and factors influencing survival. Methods. Charts of all patients whose conditions were diagnosed as malignant mesothelioma were abstracted and analyzed by statistical software. Results. The male-to-female ratio was 4:1. The age distribution was younger than 45 years of age, 10%; 45-54 years of age, 12%; 55-64 years of age, 37%; 65-74 years of age, 33%; and 75 years of age or older, 8%. Both mean and median ages were 58 years. Among the 32 patients in whom asbestos exposure was recorded, 24 had documented exposure. The sites were pleura, 73%; peritoneum, 20%; and both, 6%. The histologic types were epithelial, 51%; sarcomatous, 10%; mixed, 15%; and not specified, 24%. The stage at presentation was Stage I, 37%; II, 39%; III, 12%; IV, 6%; and unknown, 6%. The common symptoms in pleural disease were dyspnea and pain; in peritoneal disease, abdominal distension and pain were common. The median time from first symptom to diagnosis was 3 months (range, 0-23 months). The median survival after the appearance of symptoms, the diagnosis, and the treatment were 13, 10, and 8 months, respectively. Conclusions. The survival was independent of age, sex, and smoking behavior. It was longer in patients with earlier-stage disease, a good performance status, a longer duration of symptoms, an absence of pain, and who were treated with combined surgery and chemotherapy. Chemotherapy using anthracyclines yielded more remissions (9 of 21) than that using nonanthracyclines (0 of 13). The remission rate after primary chemotherapy with anthracyclines (7 of 16) may be higher than in recurrent tumor (2 of 14). In future trials, stratification into primary chemotherapy and chemotherapy of recurrent cancer is suggested. There is a need for multitechnique trials incorporating primary chemotherapy.

KW - doxorubicin

KW - mesothelioma

KW - metachronous cancers

KW - multitechnique therapy

KW - pirarubicin

KW - primary chemotherapy

KW - prochlorperazine

UR - http://www.scopus.com/inward/record.url?scp=0026442078&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026442078&partnerID=8YFLogxK

U2 - 10.1002/1097-0142(19921215)70:12<2969::AID-CNCR2820701239>3.0.CO;2-A

DO - 10.1002/1097-0142(19921215)70:12<2969::AID-CNCR2820701239>3.0.CO;2-A

M3 - Article

C2 - 1451080

AN - SCOPUS:0026442078

VL - 70

SP - 2969

EP - 2979

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 12

ER -